openPR Logo
Press release

Los Angeles Law Firm Now Investigating Transvaginal Mesh Injury Claims

11-24-2011 07:31 AM CET | Politics, Law & Society

Press release from: Nadrich & Cohen, LLP

Los Angeles, CA, November 21, 2011 – Nadrich & Cohen, LLP, a national law firm dedicated to protecting the rights of individuals who have been harmed by defective drugs, is now investigating cases nationwide involving patients who have developed bladder cancer after using the prescription drug Actos.

As part of its effort to reach out to Actos users in all 50 states, Nadrich & Cohen has launched a new website devoted to Actos bladder cancer claims. The new website at http://www.sideeffectactos.com offers a complete history of the health warnings associated with Actos, an overview of the symptoms of bladder cancer as well as regular news updates on Actos research, Actos lawsuits and the future of Actos on the worldwide market.

In June of 2011, both France and Germany issued a recall of Actos and pulled the drug off the market after research indicated that long-term Actos users had a significantly increased risk for developing bladder cancer and other serious conditions.

That same month, the U.S. Food and Drug Administration issued new warnings for Actos regarding the bladder cancer risk but declined to initiate a recall of the drug. Most recently, the European Medical Agency issued a statement supporting the use of Actos for patients with Type 2 diabetes in cases where other forms of treatment have been unsuccessful.

Following the FDA’s warning, a number of Actos side effects lawsuits have been filed in federal courts across the country. According to court documents, the lawsuits allege that not only did Actos cause bladder cancer in the plaintiffs but Takeda Pharmaceuticals staged a concerted effort to conceal the drug’s potential side effects. A hearing has been scheduled for December 1, 2011 at which time the U.S. Judicial Penal on Multidistrict Litigation will decide whether the Actos lawsuits will be consolidated for trial in the U.S. District Court for the Southern District of Illinois.

While the future of Actos remains uncertain, Takeda Pharmaceuticals is continuing to manufacture Actos and profit from its sale in countries around the world. Since its introduction to the market, Actos has been a leading moneymaker for the Japan-based drug-maker, generating billions of dollars annually in revenue.

If you or a loved one has developed bladder cancer or other serious health conditions after taking Actos, the experienced legal team at Nadrich & Cohen, LLP is here to help. Our Actos side effects website is your one-stop source for the latest Actos news and information. Contact us today at 1-800-722-0765 for a free initial evaluation of your Actos bladder cancer injury claim.

###

Contact:

Nadrich & Cohen, LLP

12100 Wilshire Blvd Suite 1250

Los Angeles, CA 90025

(800) 722-0765

http://www.personalinjurylawcal.com

Nadrich & Cohen, LLP is a nationally recognized law firm specializing in handling personal injury claims across the country. In addition to handling transvaginal mesh injury claims, we also handle claims involving harmful prescription drugs such as Actos and Yaz, defective medical devices, such as the DePuy hip implant and accidents caused by negligence, including car accidents, motorcycle accidents and bicycle accidents.

Nadrich & Cohen, LLP
12100 Wilshire Blvd Suite 1250
Los Angeles, CA 90025
800-718-4658
Jennifer Poole
jpoole@personalinjurylawcal.com

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Los Angeles Law Firm Now Investigating Transvaginal Mesh Injury Claims here

News-ID: 201882 • Views: 1401

More Releases from Nadrich & Cohen, LLP

Johnson & Johnson Defends Withdrawal of PMA for Rejected Hips
Nadrich & Cohen, LLP reports that Johnson & Johnson is defending its withdrawal of a PMA for a rejected metal hip device that was reportedly sold overseas. Los Angeles, CA, February 16, 2012 – The Johnson & Johnson Company is facing more criticism after a recent New York Times article revealed that the company continued to market a metal hip resurfacing system overseas, despite the fact that the FDA failed to
Actos Bladder Cancer Lawsuits Continue to Mount as Attorneys Push for Consolidat …
With new Actos bladder cancer lawsuits being filed every day, the plaintiffs and their attorneys are urging for the consolidation of these cases. Some 3500 Actos lawsuits have been filed in state and federal courts across the country, including Illinois, New York, New Jersey, Ohio and California. The law firm of Nadrich & Cohen LLP is currently investigating claims from Actos users in all 50 states who claim they developed
New Actos Bladder Cancer Resource Center Offers Answers to Concerned Patients
Los Angeles, CA, December 6, 2011 -- Nadrich & Cohen LLP, a prominent national law firm, has established a new website geared towards helping Actos users who developed bladder cancer after taking the drug. Visitors to the new site, www.SideEffectActos.com, can find the latest updates, news and information on the Actos bladder cancer litigation. The link between Actos and bladder cancer first came to light in September 2010, when the
New Vaginal Mesh Safety Recommendations Issued
National law firm Nadrich & Cohen LLP is endorsing new recommendations issued by the American College of Obstetricians and Gynecologists (ACOG) and the American Urogynecologic Society (AUGS) regarding the use of transvaginal mesh to treat pelvic organ prolapse in certain women. In a joint statement, the two organizations called for physicians to limit their use of vaginal mesh only to high-risk women for whom other treatment methods would not be

All 5 Releases


More Releases for Actos

Nadrich & Cohen LLP Clarifies Statements Regarding Actos Bladder Cancer Lawsuits
Los Angeles, CA, January 24, 2012 – National law firm Nadrich & Cohen LLP would like to clarify previous statements regarding the pending Actos bladder cancer litigation. Earlier press releases included incorrect information regarding the total number of Actos lawsuits filed against the drug’s manufacturer, Takeda Pharmaceuticals. Those releases, based on media reports, estimated the number of lawsuits filed in state and federal courts nationwide in connection with Actos numbered
Federal Panel Votes to Consolidate Actos Bladder Cancer Lawsuits
Nadrich & Cohen LLP reports that a federal judicial panel has voted to consolidate pending Actos bladder cancer claims into a multidistrict litigation for pretrial proceedings. Los Angeles, CA, January 5, 2012 – Plaintiffs in the Actos bladder cancer litigation have successfully moved to have the federal lawsuits consolidated into a multidistrict litigation for pretrial proceedings. The cases will be transferred to the Western District Court of Louisiana, with the
More Actos Bladder Cancer Lawsuits Filed in Los Angeles
Nadrich & Cohen LLP reports that new lawsuits have been filed in Los Angeles against the maker of Actos by two patients who allege the drug caused bladder cancer. Los Angeles, CA, December 30, 2011 – As Takeda Pharmaceuticals continues to battle litigation over its Type 2 diabetes drug Actos, three additional lawsuits were filed in a Los Angeles court. The newest claims join the thousands of other Actos lawsuits that
Nadrich & Cohen Now Reviewing Actos Bladder Cancer Claims
Los Angeles, CA, December 12, 2011 – Nadrich & Cohen LLP, a prominent national law firm, is now reviewing claims from Actos users in all 50 states who developed bladder cancer after taking the drug. In an effort to connect with even more Actos users across the country, the firm has established an online resource center at www.SideEffectActos.com. Actos was approved by the U.S. Food and Drug Administration to treat adults
FDA Delays Actos Combo Drug Review as Actos Bladder Cancer Lawsuits Continue to …
Los Angeles, CA, December 9, 2011 – As Actos bladder cancer lawsuits continue to mount, the Food and Drug Administration has opted to delay its review of a new Type 2 diabetes drug that combines Actos with algoliptin. The FDA’s decision represents another blow to Japanese drug-maker Takeda Pharmaceuticals, who may face as many 10,000 lawsuits from Actos users who claim they developed bladder cancer after taking the drug. The
Actos Bladder Cancer Lawsuits Expected to Top 10,000
Los Angeles, CA, December 2, 2011 --- The number of lawsuits stemming from Actos bladder cancer claims may reach more than 10,000, according to a Bloomberg report. In response, national law firm Nadrich & Cohen, LLP has launched a new Actos bladder cancer resource website to assist patients in filing their claims. Visitors to www.SideEffectActos.com can read up on the link between Actos and bladder cancer, get the latest updates